Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study

Annual PSA screening in BRCA2 PGV carriers confirmed a higher incidence of csPC and detection of clinically relevant tumours in comparison to noncarriers. For the first time, we confirm that PSA screening in BRCA1 PGV carriers results in early detection of NCCN IR-U/HR PC. Systematic PSA screening is recommended for BRCA2 PGV carriers and should be considered for BRCA1 PGV carriers.

Authors

Institutions

Publication Details

Journal
European Urology
Published
2026-02-01
DOI
https://doi.org/10.1016/j.eururo.2026.01.031
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study

Dorothy Halliday, Karol Axcrona, D.Gareth R. Evans, Merrie Gowie et al.
European Urology
Prostate Cancer Diagnosis and Treatment
article

Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study

Dorothy Halliday, Karol Axcrona, D.Gareth R. Evans, Merrie Gowie, Eveline W Blom, Mark N. Brook, Tim Dudderidge, Jana McHugh, Kathryn Myhill, Monique Esther van Leerdam, Nicola Nicolai, Rachel Susman, Marta Cardoso, Michiel Vlaming, Alison Falconer, Lesley Andrews, Marion Harris, Camilla Huber, Lucia Copáková, Elena Castro, Rennert Gad, Jennifer Pope, Joanne McKinley, Wendy AG van Zelst-Stams, Jeanette Rothwell, Aaronson Nk, Kara N. Maxwell, Marielle W.G. Ruijs, Palle J.S. Osther, Mateja Krajc, Judy Kirk, Mara Cruellas, Monica Salinas, Vincent Khoo, Judith Offman, Kai-Ren Ong, Mohnish Suri, Ruth Cleaver, Munaza Ahmed, Eduard Pérez-Ballestero, Derek J. Rosario, Sibel Saya, David Gallagher, Zsofia Kote-Jarai, Eli Marie Grindedal, Declan G. Murphy, Manuel R. Teixeira, Rosemarie Davidson, John S. McGrath, Lynn Greenhalgh, Karen Tricker, Kerstin Rhiem, Julian Barwell, Michael J. Hall, William D. Foulkes, Angela F. Brady, Teresa Ramon y Cajal, Annelie Liljegren, Henrik Gronberg, Christina G. Hutten, Lovise Maehle, Jo Lyman, Armen Aprikian, Christos Mikropoulos, Irene Jobson, Natalie Taylor, Lidia Feliubadaló, Alan Donaldson, Rakefet Chen-Shtoyerman, Christi J. van Asperen, David Dearnaley, Jacquelyn Powers, Jackie Cook, Chris H. Bangma, Jan Lubinski, Elizabeth K. Bancroft, Freddie C. Hamdy, Cezary Cybulski, Stefan Carlsson, Jan C. Oosterwijk, Janneke Ringelberg, Rosalind A. Eeles, Vedang Murthy, Banu Arun, Rachel Williams, Allan Spigelman, Lyon Mascarenhas, Diana M. Eccles, Vishakha Tripathi, Marc Tischkowitz, Saundra Buys, Eitan Friedman, Margreet G.E.M. Ausems, Hans Lilja, Dominika Wokolorczyk, Lisa Walker, Paul James, Lucy Side, Geoffrey J. Lindeman, Audrey Ardern-Jones, Tessy Thomas, Amy Taylor, Rita K. Schmutzler, Matthew Hogben, Louise Izatt, Ashraf Azzabi, Nicholas Pachter, Sarah Thomas, Anita Mitra, Syed Hussain, Mark Longmuir
article en

Abstract

Annual PSA screening in BRCA2 PGV carriers confirmed a higher incidence of csPC and detection of clinically relevant tumours in comparison to noncarriers. For the first time, we confirm that PSA screening in BRCA1 PGV carriers results in early detection of NCCN IR-U/HR PC. Systematic PSA screening is recommended for BRCA2 PGV carriers and should be considered for BRCA1 PGV carriers.

European Urology
Hebron University (PS), Oslo University Hospital (NO), Rush University Medical Center (US), Fox Chase Cancer Center (US), North Bristol NHS Trust (GB), The Royal Melbourne Hospital (AU), Royal Marsden NHS Foundation Trust (GB), University Medical Center Groningen (NL), Memorial Sloan Kettering Cancer Center (US), Karolinska University Hospital (SE), NorthShore University HealthSystem (US), University College London Hospitals NHS Foundation Trust (GB), The University of Texas MD Anderson Cancer Center (US), Institute of Cancer Research (GB), Radboud University Nijmegen (NL), University of Liverpool (GB), Imperial College Healthcare NHS Trust (GB), University of Leicester (GB), The University of Melbourne (AU), Queen Mary University of London (GB), University of Groningen (NL), Technion – Israel Institute of Technology (IL), Walter and Eliza Hall Institute of Medical Research (AU), Guy's and St Thomas' NHS Foundation Trust (GB), Homi Bhabha National Institute (IN), University of Utah (US), University of Exeter (GB), Royal Brisbane and Women's Hospital (AU), Royal Surrey County Hospital (GB), Manchester Academic Health Science Centre (GB), New Cross Hospital (GB), Sheba Medical Center (IL), Leiden University Medical Center (NL), Maastricht University Medical Centre (NL), Akershus University Hospital (NO), Great Ormond Street Hospital for Children NHS Foundation Trust (GB), London North West Healthcare NHS Trust (GB), Peter MacCallum Cancer Centre (AU), Huntsman Cancer Institute (US), Churchill Hospital (GB), Royal Devon and Exeter Hospital (GB), Cancer Research UK (GB), King Edward Memorial Hospital (AU), Princess Anne Hospital (GB), Royal Hallamshire Hospital (GB), McGill University Health Centre (CA), Jewish General Hospital (CA), Erasmus MC (NL), University Hospitals of Leicester NHS Trust (GB), Cambridge University Hospitals NHS Foundation Trust (GB), Nottingham City Hospital (GB), Radboud University Medical Center (NL), University Hospital Southampton NHS Foundation Trust (GB), Westmead Hospital (AU), Karolinska Institutet (SE), The Netherlands Cancer Institute (NL), University Medical Center Utrecht (NL), Institute of Oncology Ljubljana (SI), Maastricht University (NL), Institut d'Investigació Biomédica de Bellvitge (ES), Institute of Cancer Research (CA), Vejle Sygehus (DK), Liverpool Women's Hospital (GB), National Institute of Cardiovascular Diseases (SK), Integrated Oncology (United States) (US), Birmingham Women's Hospital (GB), Hospital Universitario 12 De Octubre (ES), Instituto Português de Oncologia Francisco Gentil (PT), Prince of Wales Hospital (AU), IPO Porto (PT), St George's Hospital (GB), Region of Southern Denmark (DK), Monash Health (AU), Sheffield Children's NHS Foundation Trust (GB), Newcastle upon Tyne Hospital (GB), Vall d'Hebron Hospital Universitari (ES), St Michael's Hospital (GB), Westmead Institute for Medical Research (AU), Oxford University Hospitals NHS Trust (GB), Center for Genomic Science (IT), The Kinghorn Cancer Centre (AU), University Hospital Cologne (DE), St. James's Hospital (IE), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Advanced Centre for Treatment, Research and Education in Cancer (IN), Queen Elizabeth University Hospital (GB), International Hereditary Cancer Center (PL), Hersenstichting (NL), Vall d'Hebron Institute of Oncology (ES), University College London (GB), Rush University (US), Ariel University (IL), University of Pennsylvania (US), Pomeranian Medical University (PL)
Good health and well-being
Openalex Percentile: Top 50%
Prostate Cancer Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.